Asahi Intecc said early this month that its board of directors agreed to acquire RetroVascular in a deal worth approximately $25.9 million.
Menlo Park, Calif.-based RetroVascular is developing cardiological tools for percutaneous transluminal coronary angioplasty procedures, specifically to treat chronic total occlusions.
Asahi said that it has maintained a collaborative relationship with RetroVascular to develop the PTCA treatment, which incorporates the use of plasma energy technology with the intention of improving PTCA treatment results.
Asahi Intecc said it will look for ways to incorporate the plasma energy technologies into its own devices, with hopes that it will be able to expand into fields outside cardiovascular use.
The company added that it hopes to use RetroVascular’s location in Silicon Valley “as a base for gathering and surveying most-advanced information,” according to a press release.
In April, Asahi Intecc revealed plans to begin direct sales of its coronary percutaneous transluminal coronary angioplasty guidewires in the US, which were previously only distributed by Abbott‘s (NYSE:ABT) vascular division.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.